Phase 1 Data Support Further Investigation of RMC-6236 in KRAS-Mutant NSCLC

Kathryn C. Arbour, MD, discusses the unique mechanism of action of RMC-6236, the preliminary efficacy and safety findings for this agent in patients with KRAS-mutant NSCLC, and future directions for the RMC-6236-001 trial.

Related Keywords

Memorial Sloan Kettering Cancer Center ,New York ,United States , ,Kathrync Arbour ,D ,Rmc 6236 ,Patients With Kras Mutant Nsclc ,Rmc 6236 001 Trial ,